Physician profile
Dania A Kamp
NPI 1386647980
$427.62
in general payments reported to CMS, 2019-2025
18 companies · $138 in 2025
The $138 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $124 · 2022: $28.84 · 2023: $30.95 · 2024: $106 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $275.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $58.65 | 2024-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $58.18 | 2022-2025 | Airsupra, Breztri |
| Xeris Pharmaceuticals, INC. | $40.27 | 2024-2025 | Keveyis |
| Abiomed | $28.94 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $26.54 | 2021 | |
| Abbvie INC. | $23.96 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $23.71 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.67 | 2021 | |
| Horizon Therapeutics Plc | $16.97 | 2023 | Krystexxa |
| Amgen INC. | $16.94 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.90 | 2025 | Caplyta |
| Roche Diagnostics Corporation | $15.99 | 2021 | |
| Lilly USA, LLC | $14.99 | 2025 | Kisunla |
| Medtronic, INC. | $14.85 | 2024 | Intellis Adaptivestim |
| Eisai INC. | $14.05 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $13.47 | 2024 | |
| Pfizer INC. | $13.08 | 2021 | |
| Alexion Pharmaceuticals, INC. | $11.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dania Kamp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.